{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:04:05Z","timestamp":1783703045939,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"am","delay-in-days":404,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.dmpk.2024.101027","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T09:04:35Z","timestamp":1719911075000},"page":"101027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders"],"prefix":"10.1016","volume":"58","author":[{"given":"Kenta","family":"Sakaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-3789","authenticated-orcid":false,"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Miyadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Nakatsugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2024.101027_bib1","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fphar.2018.01560","article-title":"Role of vonoprazan in Helicobacter pylori eradication therapy in Japan","volume":"9","author":"Sugimoto","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101027_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101027_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin associated ulcer recurrence randomised phase 3 study","volume":"67","author":"Kawai","year":"2018","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101027_bib4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2024.101027_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fphar.2020.00053","article-title":"Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo","volume":"11","author":"Wang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmpk.2024.101027_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchromb.2016.01.051","article-title":"A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquidchromatography-tandem mass spectrometry","volume":"1015\u20131016","author":"Yoneyama","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101027_bib7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.transproceed.2013.11.023","article-title":"Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus","volume":"46","author":"Hattori","year":"2014","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101027_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1067\/mcp.2002.126177","article-title":"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein","volume":"72","author":"Kurata","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101027_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/03602532.2016.1239630","article-title":"Perspective: 4\u03b2-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A","volume":"49","author":"Mao","year":"2017","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101027_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101027_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03309.x","article-title":"4\u03b2-hydroxycholesterol as an endogenous marker for CYP3A4\/5 activity. Stability and half-life of elimination after induction with rifampicin","volume":"67","author":"Diczfalusy","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101027_bib12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1365-2125.2007.03078.x","article-title":"Time course of the increase in 4\u03b2-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy","volume":"65","author":"Wide","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmpk.2024.101027_bib13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-012-1266-x","article-title":"Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients","volume":"68","author":"Naito","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101027_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.dmpk.2016.04.001","article-title":"Relationship between the plasma fentanyl and serum 4\u03b2-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain","volume":"31","author":"Ishida","year":"2016","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"43","key":"10.1016\/j.dmpk.2024.101027_bib15","doi-asserted-by":"crossref","first-page":"16029","DOI":"10.3748\/wjg.v20.i43.16029","article-title":"CYP2C19 polymorphism influences Helicobacter pylori eradication","volume":"20","author":"Kuo","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.dmpk.2024.101027_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmpk.2024.101027_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.13959","article-title":"Letter: CYP3A4\/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan","volume":"45","author":"Sugimoto","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.dmpk.2024.101027_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/antibiotics9100645","article-title":"Effect of antibiotic susceptibility and CYP3A4\/5 and CYP2C19 genotype on the outcome of vonoprazan-containing Helicobacter pylori eradication therapy","volume":"9","author":"Sugimoto","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.dmpk.2024.101027_bib19","unstructured":"Indiana University School of Medicine, Flockhart Table: P450 Drug Interaction Table. https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx; [accessed 5 May 2024]."},{"issue":"5","key":"10.1016\/j.dmpk.2024.101027_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0091270010376193","article-title":"In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects","volume":"51","author":"Shoaf","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmpk.2024.101027_bib22","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1248\/bpb.b15-00241","article-title":"Saturated metabolism of voriconazole N-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses","volume":"38","author":"Yamada","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101027_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.dmpk.2015.08.008","article-title":"CYP3A activity based on plasma 4\u03b2-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine","volume":"30","author":"Naito","year":"2015","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmpk.2024.101027_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2024.101027_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cca.2014.12.024","article-title":"Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients","volume":"441","author":"Naito","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101027_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF01059685","article-title":"The clinical pharmacokinetics of phenytoin","volume":"5","author":"Martin","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.dmpk.2024.101027_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clinbiochem.2019.05.003","article-title":"Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4\/5-related markers in rheumatoid arthritis patients","volume":"69","author":"Naito","year":"2019","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101027_bib28","first-page":"350","article-title":"Impact of pregnancy on pharmacokinetics of medications","volume":"20","author":"Hebert","year":"2013","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"17\u201318","key":"10.1016\/j.dmpk.2024.101027_bib29","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cca.2011.10.013","article-title":"Pharmacogenetic biomarkers: cytochrome P450 3A5","volume":"413","author":"MacPhee","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dmpk.2024.101027_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.preghy.2019.07.002","article-title":"Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension","volume":"17","author":"Taguchi","year":"2019","journal-title":"Pregnancy Hypertens"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101027_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.13355","article-title":"Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients","volume":"126","author":"Hoshikawa","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101027_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","article-title":"Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response","volume":"87","author":"Rivory","year":"2002","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101027_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00228-009-0625-8","article-title":"Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects","volume":"65","author":"Kodaira","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101027_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study","volume":"67","author":"Kawai","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101027_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","article-title":"Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials","volume":"45","author":"Miwa","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmpk.2024.101027_bib36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00228-021-03162-5","article-title":"Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia","volume":"77","author":"Suzuki","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101027_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpt.1596","article-title":"Quantitative prediction of CYP3A4- and CYP3A5-mediated drug interactions","volume":"107","author":"Guo","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101027_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00498254.2010.523734","article-title":"CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity","volume":"41","author":"Christensen","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2024.101027_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsbmb.2012.09.012","article-title":"Interplay between vitamin D and the drug metabolizing enzyme CYP3A4","volume":"136","author":"Wang","year":"2013","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T03:48:44Z","timestamp":1731124124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":38,"alternative-id":["S1347436724000338"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101027","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101027"}}